0IRF.IL

Healthcare Drug Manufacturers - Specialty & Generic

Evotec SE

€2.92

-0.03 -0.85% today

Price History

Not enough data

Key Stats

Market Cap

—

Avg Volume

39,571

EPS

-€0.58

52W High

€7.29

52W Low

€2.71

Div. Yield

0.0%

Valuation

P/B Ratio

0.44

P/S Ratio

0.71

EV/EBITDA

25.89

EV/Revenue

3.66

Margins

Gross Margin 26.4%

Operating Margin 5.5%

Net Margin (12.9%)

EBITDA Margin 14.1%

Growth & Returns

Revenue Growth (YoY)

(1.1%)

Return on Equity

(8.4%)

Return on Assets

1.2%

Liquidity & Leverage

Current Ratio

2.10

Quick Ratio

1.87

Debt / Equity

0.45

Total Cash

620.85M

Total Debt

534.15M

About

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.